Mai Capital Management Regenerx Biopharmaceuticals Inc Transaction History

Mai Capital Management

  • $9.87 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 19, 2022
BUY
$0.15 - $0.22 $3,000 - $4,400
20,000 New
20,000 $3,000

About REGENERX BIOPHARMACEUTICALS INC

RGRX Quotes by TradingView
  • Ticker RGRX
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,550,000
  • Description
  • RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; ...
More about RGRX
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email